Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received regulatory approval in March 2025 for uncomplicated urinary tract infections under the name Blujepa and remains under FDA review for gonorrhea. The compound acts as a dual inhibitor of DNA gyrase and topoisomerase IV with a distinct binding mode designed to overcome common fluoroquinolone resistance mechanisms. Developers highlight gepotidacin’s potential to spare gut microbiota and address safety concerns associated with older fluoroquinolones; ongoing review for gonorrhea reflects an urgent public‑health need as resistance limits current treatment options.